The agreement will drive the discovery of more effective treatments for cardiovascular disease and development of safer drugs with the preclinical implementation of advanced human heart models
Read MoreThe in-vitro studies performed in Glauconix's co-culture 3D conventional human outflow model confirm efficacy
Read More3D Human Tissue Retina Vasculature model provides a new and novel approach to rapidly and efficiently screening numerous therapies for diabetic retinopathy and diabetic macular edema.
Read MoreThis 2019 award sheds light on Iunisov.com's far-reaching expertise in digital marketing and lead generation. These competencies span across Europe and North America for both B2B and B2C companies and include various economy sectors. — Andrei Iunisov, CEO, Iunisov.com
Read MoreCROs are finding themselves operating in an increasingly competitive market, where true differentiation is hard to achieve. In order to stand out from the competition, today's CROs need to offer something more.
Read MoreWith so much at stake, where do you start when considering the right long-term strategic CRO partner? With technology and the market both priming CROs to step in as industry innovators, what attributes should sponsors look for in 'best-in-class' strategic partners?
Read MoreRxPense®, an intelligent and connected medication management and remote monitoring solution, can significantly increase reliability of clinical trial data by ensuring participants take their doses on time and only when prescribed. CRO's benefit from enhanced and secure data collection, medication security, remote patient monitoring, and vitals reporting at the point of access - all at drastically reduced cost.
Read MoreImaBiotech, a CRO company developing and offering mass spectrometry imaging (MSI) services, applications, and software, announces today a license agreement with Lawrence Berkeley National Laboratory (Berkeley Lab) to "OpenMSI" intellectual property to support ImaBiotech Multimaging™ technology.
Read MorePHASTAR Inc. has been incorporated in the US and will start offering industry leading statistical and medical writing services from a US base within the next few weeks. The first US PHASTAR office will be based in Research Triangle Park, North Carolina, with an experienced US based management team to be the cornerstones of our North American business. - See more at: http://www.industrytoday.co.uk/
Read More